Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Champions Oncology, Inc. - Common Stock (NQ: CSBR )

8.970 +0.080 (+0.90%)
Streaming Delayed Price Updated: 9:30 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Champions Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Champions Oncology Reports Record Quarterly Revenue of $14.3 Million
Via ACCESSWIRE
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022
Via ACCESSWIRE
Champions Oncology Reports Record Quarterly Revenue of $13.7 Million
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Via ACCESSWIRE
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Earnings Scheduled For September 8, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its second quarter. • Sono Group (NASDAQ:SEV) is estimated to report earnings for its second... 
Via Benzinga
Earnings Preview For Champions Oncology
Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Thursday, 2022-09-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Record Annual Revenue of $49.1 Million 
From Champions Oncology, Inc.
Via AccessWire
A Preview Of Champions Oncology's Earnings
Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Thursday, 2022-07-21. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022
HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven... 
From Champions Oncology, Inc.
Via AccessWire
Earnings Scheduled For July 21, 2022
Companies Reporting Before The Bell • SAP (NYSE:SAP) is projected to report quarterly earnings at $1.15 per share on revenue of $7.56 billion. 
Via Benzinga
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics
HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative... 
From Champions Oncology, Inc.
Via AccessWire
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Champions Oncology, Inc.
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here's How Much You Would Have Made Owning Champions Oncology Stock In The Last 5 Years
Champions Oncology (NASDAQ:CSBR) has outperformed the market over the past 5 years by 7.88% on an annualized basis. Buying $1,000 In CSBR: 5 years ago, an investor could have... 
Via Benzinga
Champions Oncology Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q3, Champions Oncology (NASDAQ:CSBR) earned $787.00 thousand, a 184.12% increase from the preceding quarter. Champions Oncology also posted a... 
Via Benzinga
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million
HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven... 
From Champions Oncology, Inc.
Via AccessWire
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
Earnings Preview For Champions Oncology
Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022
HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven... 
From Champions Oncology, Inc.
Via AccessWire
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors
HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven... 
From Champions Oncology, Inc.
Via AccessWire
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates
HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven... 
From Champions Oncology, Inc.
Via AccessWire
Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs
HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology,... 
From Champions Oncology, Inc.
Via AccessWire
Looking Into Champions Oncology's Return On Capital Employed
According to Benzinga Pro, during Q2, Champions Oncology (NASDAQ:CSBR) earned $277.00 thousand, a 261.05% increase from the preceding quarter. Champions Oncology also posted a... 
Via Benzinga
Champions Oncology Reports Record Quarterly Revenue of $11.8 Million
Reported income from operations of $263,000 HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming... 
From Champions Oncology, Inc.
Via AccessWire
Earnings Scheduled For December 13, 2021
Companies Reporting Before The Bell • Qudian (NYSE:QD) is projected to report quarterly earnings at $0.18 per share on revenue of $56.15 million. Companies... 
Via Benzinga
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 13, 2021
HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report... 
From Champions Oncology, Inc.
Via AccessWire
Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus
HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned... 
From Champions Oncology, Inc.
Via AccessWire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.